Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of STAR0602 in advanced solid tumors
2023-505334-10-01Phase 2Authorised
- Sponsor
- Marengo Therapeutics
- Start
- Jul 2024
- Modality
- Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 2, single-arm trial of invikafusp alfa in Nonhematologic neoplasms, sponsored by Marengo Therapeutics. Primary endpoints: Safety and tolerability of STAR0602 and Pharmacokinetics of STAR0602. Planned start Jul 2024; status: authorised.
02
Drugs
invikafusp alfa
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2023-505334-10-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505334-10-01.